Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Jin Yang Pharmaceutical Co., Ltd. (007370:KRX), powered by AI.
Jin Yang Pharmaceutical Co., Ltd. is currently trading at ₩4,105. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Jin Yang Pharmaceutical Co., Ltd. on Alpha Lenz.
Jin Yang Pharmaceutical Co., Ltd.'s P/E ratio is 2.6.
“Jin Yang Pharmaceutical Co., Ltd. trades at a P/E of 2.6 (undervalued) with strong ROE of 15.9%. 3Y revenue CAGR of 16.5% highlights clear growth momentum.”
Ask for details →Jin Yang Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, concentrating on the research, development, manufacturing, and marketing of pharmaceutical products. The company is dedicated to advancing medical care and improving patient outcomes by providing innovative and high-quality medications. Jin Yang focuses on a wide range of therapeutic areas, including oncology, cardio-metabolic disorders, and infectious diseases, addressing the needs of both local and international markets. As a pharmaceutical entity, Jin Yang is integral to the healthcare sector, contributing to the industry's overall growth and technological advancements. The company's involvement in producing essential medicines not only supports healthcare providers but also plays a crucial role in ensuring the availability and accessibility of life-saving treatments. By emphasizing rigorous research and development, Jin Yang Pharmaceutical Co., Ltd. upholds its commitment to enhancing health care systems and patient care worldwide.
“Jin Yang Pharmaceutical Co., Ltd. trades at a P/E of 2.6 (undervalued) with strong ROE of 15.9%. 3Y revenue CAGR of 16.5% highlights clear growth momentum.”
Ask for details →Jin Yang Pharmaceutical Co., Ltd. (ticker: 007370) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $58.0B.
The current price is ₩4,105 with a P/E ratio of 2.6x and P/B of 0.36x.
ROE is 15.93% and operating margin is 2.09%. Annual revenue is $120.7B.